Get started
Monopar Therapeutics IncMonopar Therapeutics IncMonopar Therapeutics Inc

Monopar Therapeutics Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast

A40JML chart


Full chart

A40JML upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪203.93 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.9826 EUR
Net income (FY)
‪−15.06 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪3.96 M‬
Beta (1Y)
2.69

Employees


Employees (FY)
16
Change (1Y)
+6 +60.00%
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−941.01 K‬ EUR

About Monopar Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Chandler Drew Robinson
Website
monopartx.com
Headquarters
Wilmette
Founded
2014
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

A40JML news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Check out other big names from the same industry as A40JML.

Frequently Asked Questions


The current price of A40JML is 33.6000 EUR — it has increased by 4.35% in the past 24 hours. Watch Monopar Therapeutics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Monopar Therapeutics Inc stocks are traded under the ticker A40JML.
A40JML stock has risen by 30.23% compared to the previous week, the month change is a 11.26% rise, over the last year Monopar Therapeutics Inc has showed a 26.32% increase.
We've gathered analysts' opinions on Monopar Therapeutics Inc future price: according to them, A40JML price has a max estimate of 66.91 EUR and a min estimate of 35.22 EUR. Watch A40JML chart and read a more detailed Monopar Therapeutics Inc stock forecast: see what analysts think of Monopar Therapeutics Inc and suggest that you do with its stocks.
A40JML reached its all-time high on Feb 10, 2025 with the price of 52.5000 EUR, and its all-time low was 24.4000 EUR and was reached on Apr 7, 2025. View more price dynamics on A40JML chart.
See other stocks reaching their highest and lowest prices.
A40JML stock is 4.17% volatile and has beta coefficient of 2.69. Track Monopar Therapeutics Inc stock price on the chart and check out the list of the most volatile stocks — is Monopar Therapeutics Inc there?
Today Monopar Therapeutics Inc has the market capitalization of ‪203.93 M‬, it has increased by 14.16% over the last week.
Yes, you can track Monopar Therapeutics Inc financials in yearly and quarterly reports right on TradingView.
Monopar Therapeutics Inc is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
A40JML earnings for the last quarter are −2.65 EUR per share, whereas the estimation was −1.06 EUR resulting in a −149.09% surprise. The estimated earnings for the next quarter are −0.43 EUR per share. See more details about Monopar Therapeutics Inc earnings.
Monopar Therapeutics Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
A40JML net income for the last quarter is ‪−10.55 M‬ EUR, while the quarter before that showed ‪−1.17 M‬ EUR of net income which accounts for −800.95% change. Track more Monopar Therapeutics Inc financial stats to get the full picture.
No, A40JML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 16 employees. See our rating of the largest employees — is Monopar Therapeutics Inc on this list?
Like other stocks, A40JML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monopar Therapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.